Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

Shanghai Public Health Clinical Center

Status and phase

Completed

Phase 3

Conditions

COVID-19

Pneumonia, Pneumocystis

Coronavirus

Treatments

Drug: Hydroxychloroquine

Study type

Interventional

Funder types

Other

Identifiers

NCT04261517

HC-COVID-19

Details and patient eligibility

About

The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

Full description

There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China;
Participants aged over 18;
Written the informed consent.

Exclusion criteria

Hypersensitivity to chloroquine or hydroxychloroquine;
Women during pregnancy;
Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
Participants with retinal disease, hearing loss;
Participants with severe neurological and mental illness;
Subjects were considered to be unable to complete the study, or not suitable for the study by researchers.

Exit criteria: